Project Grant R01DK143601

Award Date 7/1/25
Completion Date 5/31/30
Dollars Obligated $626K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $754,400 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) program. The funding will support research by The University of Texas Southwestern Medical Center (UT Southwestern) to identify adaptive genetic pathways and understand how mutant clones expand within chronically damaged liver tissues, with the goal of developing therapeutic approaches...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $243,590 to the University of Chicago to investigate the role of the protein BNIP3 in regulating lipid homeostasis in the liver. The goal is to define the mechanisms by which BNIP3 influences the accumulation of lipid droplets, which is a key factor in the development of non-alcoholic...
This federal Project Grant award of $675,660.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on understanding the regulation and requirements for coenzyme A (CoA) biosynthesis, and how dysregulation of CoA synthesis is related to metabolic diseases...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $806,192 to support research on the role of the MRP9 protein in cholangiocyte (bile duct cell) metabolism. The research aims to elucidate how MRP9 deficiency leads to cholangiocyte injury and cell death, which can contribute to cholestatic cholangiopathies - liver disorders affecting the bile ducts. The...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) provides $172,300.00 to the University of California, Los Angeles (UCLA) to investigate the role of peroxisomal PEX family proteins in regulating hepatic bile acid and lipid metabolism. The research aims to describe how the loss of PEX6 and PEX14 proteins impacts lipid homeostasis and inter-organelle crosstalk...
This federal Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research at the Pennington Biomedical Research Center to examine the role of the mitochondrial protein SLC25A25 in the onset and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)....
This federal Project Grant award, valued at $450,000.00 and awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to elucidate the roles of the lysine acetyltransferase KAT8 in adipocyte function and its impact on lipoatrophy and systemic insulin resistance. The long-term objective is to understand how adipocyte KAT8 contributes to adipose tissue function and...
This $391,250 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support research on extracellular vesicle-dependent RNA signaling in metabolism. The project aims to identify key proteins involved in the delivery of adipose microRNAs into liver cells via extracellular vesicles, and to determine if this RNA delivery mechanism is necessary for...
This $272,133 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to study the role of lipid droplet proteins in regulating polyunsaturated fatty acid metabolism and eicosanoid production, and their impact on the progression of non-alcoholic fatty liver disease (NAFLD). The principal investigator will conduct a "recall-by-genotype" study to deeply...
This $806,452 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research investigating the mechanisms that combine type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The research aims to determine how hepatic insulin resistance can lead to the progression of NAFLD to the more severe non-alcoholic steatohepatitis (NASH), and how this...

This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the carbohydrate responsive element binding protein (ChREBP) and its isoforms in liver metabolism, metabolic diseases, and associated steatohepatitis. The $626,429 award, effective from July 1, 2025 to May 31, 2030, will employ genetic interventions in mouse models and molecular phenotyping to study the metabolic pathways and physiological impacts influenced by ChREBP isoforms. The project seeks to resolve contradictory findings on the roles of ChREBP isoforms in liver function and systemic metabolism, with the goal of enhancing understanding of metabolic disease mechanisms and potentially leading to improved diagnostic and therapeutic strategies for conditions like dyslipidemia, diabetes, and metabolic-associated fatty liver disease.

Generated 7/15/25, 4:19 AM